QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Samarium-153 DOTMP (CycloSam®), for the treatment of cancer and related diseases and conditions, announced that the U.S. Food and Drug Administration (FDA) has cleared QSAM’s investigational new drug (IND) application, which allows the company to commence Phase 1 clinical trials and the dosing of patients with bone cancer.

To read more please visit:

QSAM Biosciences Announces FDA Clearance of IND for Samarium-153 DOTMP (CycloSam®), an Investigational Radiopharmaceutical for the Treatment of Bone Cancer-QSAM Biosciences

Source: QSAM Biosciences